Over the past decade, a number of new therapies have been approved for the treatment of renal cell carcinoma (RCC; Figure 1). Most treatments are driven by clear cell histology, which represents 70% to 75% of all RCCs. Eric Jonasch, MD, Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, and Vice Chair of the NCCN Guidelines Panel, reviewed the state of the art and new systemic therapies incorporated into the 2017 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Kidney Cancer.
HassNBManolaJUzzoRG. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomized, phase 3 trial. Lancet2016;387:2008–2016.
SternbergCDavisIDMardiakJ. Pazopanib in locally advanced metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010;28:1061–1068.
ChoueiriTKHalabiSSanfordBL. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol2017;35:591–597.
ChoueiriTPowlesTEscudierBJ. Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma [abstract]. J Clin Oncol2016;34(Suppl):Abstract 4506.
MotzerRJHutsonTERenMIndependent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol2016;17:e4–5.
MotzerRJEscudierBOudardS. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet2008;372:449–456.